About

About EXO BIOLOGICS EXO Biologics is a Belgian clinical stage biotech focused on the development and the supply of exosomes and extracellular vesicles therapies. EXO biologics is the 1st company in the world to ever enter EU clinical trial with MSC derived exosomes, thus paving the European regulatory pathway for exosomes (EVENEW study). Our lead asset EXOB-001 is in phase I/II for Bronchopulmonary Dysplasia (orphan disease). EXOB-001 can be used for variety of other indications due to its safety profile and immunomodulator effect (CNS, inflammatory, Gastroenterology ,...). Our GMP manufacturing platform ExoPulse™ is accessible to all exosome developers through our wholly owned subsidiary ExoXpert. ExoXpert is the only CDMO with an exosome platform used in EU clinical trials. About EXO BIOLOGICS EXO Biologics is a Belgian clinical stage biotech focused on the development and the supply of exosomes and extracellular vesicles therapies. EXO biologics is the 1st company in the world to ever enter EU clinical trial with MSC derived exosomes, thus paving the European regulatory pathway for exosomes (EVENEW study). Our lead asset EXOB-001 is in phase I/II for Bronchopulmonary Dysplasia (orphan disease). EXOB-001 can be used for variety of other indications due to its safety profile and immunomodulator effect (CNS, inflammatory, Gastroenterology ,...). Our GMP manufacturing platform ExoPulse™ is accessible to all exosome developers through our wholly owned subsidiary ExoXpert. ExoXpert is the only CDMO with an exosome platform used in EU clinical trials. Exo Biologics is a clinical-stage company based in Belgium and a pioneer in the extracellular vesicle (EV) field. The company is currently evaluating its lead asset, EXOB-001, in a Phase I clinical trial in the EU, conducted across multiple centers. EXOB-001 is composed of EVs derived from mesenchymal stem cells (MSCs) and is being developed to treat bronchopulmonary dysplasia (BPD)—a rare inflammatory lung disease affecting preterm infants. EXOB-001 is the first MSC-EV-based product to enter clinical trials in the EU, positioning Exo Biologics as the most advanced company in this field to date. Exo Biologics offers exosomes specialized CDMO services through its subsidiary ExoXpert